Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension.

Abstract

Background ADRB1 (adrenergic receptor beta 1) responds to neuroendocrine stimulations, which have great implications in hypertension. GRK2 (G protein-coupled receptor kinase 2) is an essential regulator for many G protein-coupled receptors and subsequent cell signaling cascades, but its role as a regulator of ADRB1 and associated cardiac hypertrophy in hypertension remains to be elucidated. Methods and Results In this study, we found the expressions of GRK2 and ADRB1 in peripheral blood mononuclear cells were positively associated with blood pressure levels in hypertensive patients and with their expression in heart. In vitro evidence showed a direct interaction in ADRB1 and GRK2 and genetic depletion of GRK2 blocks epinephrine-induced upregulation of hypertrophic and fibrotic genes in cardiomyocytes. Meanwhile, we discovered a selective serotonin reuptake inhibitor paroxetine specifically blockades GRK2 and ADRB1 interaction. In vivo, paroxetine treatment ameliorates hypertension-induced cardiac hypertrophy, dysfunction, and fibrosis in animal models. We found that paroxetine suppressed sympathetic overdrive and increased the adrenergic receptor sensitivity to catecholamines. Paroxetine treatment also blocks epinephrine-induced upregulation of hypertrophic and fibrotic genes as well as ADRB1 internalization in cardiomyocytes. Coadministration of paroxetine further potentiates metoprolol-induced reductions in blood pressure and heart rate, further attenuating cardiac hypertrophy in spontaneously hypertensive rats. Furthermore, in patients with hypertension accompanied with depression, we observed that cardiac remodeling was less severe in those with paroxetine treatment compared with those with other types of anti-depressive agents. Conclusions Paroxetine promotes ADRB1 sensitivity and attenuates cardiac hypertrophy partially via blocking GRK2-mediated ADRB1 activation and internalization in the context of hypertension.

• Authors: Xuejing Sun, Mengli Zhou, Gaiyan Wen, Yun Huang, Junru Wu, Liping Peng, Weihong Jiang, Hong Yuan, Yao Lu, Jingjing Cai
• Journal: Journal of the American Heart Association (J Am Heart Assoc) Vol. 10 Issue 1 Pg. e016364 (01 05 2021) ISSN: 2047-9980 [Electronic] England
• PMID: 33372534 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Adrb1 protein, rat
• Cardiotonic Agents
• Catecholamines
• Cytochrome P-450 CYP2D6 Inhibitors
• Receptors, Adrenergic, beta-1
• Paroxetine
• G-Protein-Coupled Receptor Kinase 2

Topics

• Animals
• Cardiomegaly (etiology, metabolism, prevention & control)
• Cardiotonic Agents (pharmacology)
• Catecholamines (metabolism)
• Cytochrome P-450 CYP2D6 Inhibitors (pharmacology)
• Disease Models, Animal
• G-Protein-Coupled Receptor Kinase 2 (antagonists & inhibitors)
• Gene Knockout Techniques
• Hypertension (complications, drug therapy, metabolism)
• Paroxetine (pharmacology)
• Rats
• Receptors, Adrenergic, beta-1 (genetics, metabolism)
• Signal Transduction (drug effects)